The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Proinflammatory Effects of IL-10 During Human Endotoxemia
Open accessAbstract
IL-10 is considered a potent antiinflammatory cytokine that strongly inhibits the production of proinflammatory cytokines. Recent studies have suggested that IL-10 also has immunostimulatory properties on CD4+, CD8+ T cells, and/or NK cells, resulting in increased IFN-γ production. To determine the effect of IL-10 on IFN-γ production and related inflammatory responses in humans, 16 healthy subjects received a bolus i.v. injection of LPS (4 ng/kg) in combination with either placebo or recombinant human IL-10 (25 μg/kg), administered just before or 1 h after LPS. IL-10 treatment, particularly when administered after LPS, enhanced LPS-induced IFN-γ release, as well as the release of the IFN-γ-dependent chemokines IFN-γ-inducible protein-10 and monokine induced by IFN-γ, while inhibiting or not influencing the production of IFN-γ-inducing cytokines. In addition, IL-10 treatment enhanced activation of CTLs and NK cells after LPS injection, as reflected by increased levels of soluble granzymes. These data indicate that high-dose IL-10 treatment in patients with inflammatory disorders can be associated with undesired proinflammatory effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1209 · Cited by 3,762
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Cloning of a new cytokine that induces IFN-γ production by T cells
Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995) · Nature · doi:10.1038/378088a0 · Cited by 2,600
Self-citationde Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.915 · Cited by 1,930
Moore, K. (1993) · Annual Review of Immunology · doi:10.1146/annurev.immunol.11.1.165 · Cited by 1,884
D'Andrea, A., Aste-Amezaga, M., Valiante, N. M., Ma, X., Kubin, M., & Trinchieri, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1041 · Cited by 1,385
Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes
Rousset, F., Garcia, E., Defrance, T., Péronne, C., Vezzio, N., Hsu, D. H., Kastelein, R., Moore, K. W., & Banchereau, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1890 · Cited by 1,238
Genetic influence on cytokine production and fatal meningococcal disease
Westendorp, R. G., Langermans, J. A., Huizinga, T. W., Elouali, A. H., Verweij, C. L., Boomsma, D. I., & Vandenbrouke, J. P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)06413-6 · Cited by 800
Gérard, C., Bruyns, C., Marchant, A., Abramowicz, D., Vandenabeele, P., Delvaux, A., Fiers, W., Goldman, M., & Velu, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.2.547 · Cited by 796
Cited by
Biology and therapeutic potential of interleukin-10
Saraiva, M., Vieira, P., & O’Garra, A. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190418 · Cited by 1,118
Interleukin‐10: new perspectives on an old cytokine
Mosser, D. M., & Zhang, X. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00706.x · Cited by 1,077
Interleukin-10 Therapy—Review of a New Approach
Asadullah, K., Sterry, W., & Volk, H. D. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.4 · Cited by 946
Hu, X., & Ivashkiv, L. B. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.002 · Cited by 928
“Thus, IFNg-mediated antagonism of IL-10 function (Herrero et al., 2003; Lauw et al., 2000; Pajkrt et al., 1997) can not be explained by a SOCS1-dependent mechanism; it also appears likely that regulation of Th17 cell differentiation by IFN-g can not be explained solely by induction of SOCS1 or other SOCS proteins.”
BackgroundShaping Gene Expression in Activated and Resting Primary Macrophages by IL-10
Lang, R., Patel, D., Morris, J. J., Rutschman, R. L., & Murray, P. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2253 · Cited by 613
The paradoxical role of IL-10 in immunity and cancer
Mannino, M. H., Zhu, Z., Xiao, H., Bai, Q., Wakefield, M. R., & Fang, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.009 · Cited by 473
IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration
Deng, B., Wehling-Henricks, M., Villalta, S. A., Wang, Y., & Tidball, J. G. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103180 · Cited by 472
“For example, IL-10 generally functions as an anti-inflammatory cytokine, but supraphysiological levels of IL-10 administered during sepsis exacerbate the inflammatory response (61); administration of exogenous IL-10 at low doses is protective against graft-versus-host disease, whereas higher dosages promote lethality…”
BackgroundMocellin, S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00009-1 · Cited by 463
Strategies for use of IL‐10 or its antagonists in human disease
O'Garra, A., Barrat, F. J., Castro, A. G., Vicari, A., & Hawrylowicz, C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00635.x · Cited by 452
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418
IL-10: A Multifunctional Cytokine in Viral Infections
Rojas, J. M., Avia, M., Martín, V., & Sevilla, N. (2017) · Journal of Immunology Research · doi:10.1155/2017/6104054 · Cited by 408
Interleukin-10 and the immune response against cancer: a counterpoint
Mocellin, S., Marincola, F. M., & Young, H. A. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705358 · Cited by 402
Acute Toxoplasmosis Leads to Lethal Overproduction of Th1 Cytokines
Mordue, D. G., Monroy, F., La Regina, M., Dinarello, C. A., & Sibley, L. D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4574 · Cited by 396
Regulation of Adaptive Immunity; The Role of Interleukin-10
Ng, T. H. S., Britton, G. J., Hill, E. V., Verhagen, J., Burton, B. R., & Wraith, D. C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00129 · Cited by 354
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344
A Potential Role of Interleukin 10 in COVID-19 Pathogenesis
Lu, L., Zhang, H., Dauphars, D. J., & He, Y.-W. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.10.012 · Cited by 329
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Oft, M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0214 · Cited by 322
“given to healthy volunteers before or after a challengewith LPS, induced the cytotoxicity-mediating granzyme B and IFN-g in the serum, but decreased IL-12 p40 (47).”
BackgroundContributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Hu, X., Chakravarty, S. D., & Ivashkiv, L. B. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00707.x · Cited by 303
Targeting IL-10 Family Cytokines for the Treatment of Human Diseases
Wang, X., Wong, K., Ouyang, W., & Rutz, S. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028548 · Cited by 302
The endothelium in sepsis: Source of and a target for inflammation
Hack, C. E., & Zeerleder, S. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107001-00011 · Cited by 295
Self-citationTilg, H., van Montfrans, C., van den Ende, A., Kaser, A., van Deventer, S. J. H., Schreiber, S., Gregor, M., Ludwiczek, O., Rutgeerts, P., Gasche, C., et al. (2002) · Gut · doi:10.1136/gut.50.2.191 · Cited by 272
Self-citationEmmerich, J., Mumm, J. B., Chan, I. H., LaFace, D., Truong, H., McClanahan, T., Gorman, D. M., & Oft, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0721 · Cited by 270
Cytokines and Immune Response in the Tumor Microenvironment
Mocellin, S., Wang, E., & Marincola, F. M. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200109000-00002 · Cited by 259
Bahador, M., & Cross, A. S. (2007) · Journal of Endotoxin Research · doi:10.1177/0968051907085986 · Cited by 108
Somvanshi, P. R., Mellon, S. H., Yehuda, R., Flory, J. D., Makotkine, I., Bierer, L., Marmar, C., Jett, M., & Doyle, F. J. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00398.2019 · Cited by 55
Mumm, J. B., & Oft, M. (2013) · BioEssays · doi:10.1002/bies.201300004 · Cited by 53
Metadata
- Authors
- Lauw, F. N., Pajkrt, D., Hack, C. E., Kurimoto, M., van Deventer, S. J. H., & van der Poll, T.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-09-01
- Volume
- 165
- Issue
- 5
- Pages
- 2783-2789
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1502971607
- Cited by
- 318
- References
- 54
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.